Anti-Vascular Endothelial Growth Factor (VEGF)

    Anti-Vascular Endothelial Growth Factor Treatment for Retinal Conditions: A Systematic Review and Meta-analysis

    Pham B, Thomas SM, Lillie E, Lee T, Hamid J, Richter T, Janoudi G, Agarwal A, Sharpe JP, Scott A, Warren R, Brahmbhatt R, Macdonald E, Straus SE, Tricco AC. Anti-Vascular Endothelial Growth Factor Treatment for Retinal Conditions: A Systematic Review and Meta-analysis. BMJ Open. 2019;9(5):e022031. DOI: 10.1136/bmjopen-2018-022031.

     

    Altmetrics:

     

    Bottom Line:

    • With few exceptions, intravitreal bevacizumab was a reasonable alternative to ranibizumab and aflibercept in patients with wet choroidal neovascular age-related macular degeneration (cn-AMD), diabetic macular edema (DME), macular edema due to retinal vein occlusion (RVO-ME) and myopic choroidal neovascularization (m-CNV)
    • The choice of anti-VEGF drug may depend on specific retinal conditions, baseline visual acuity, and treatment regimen

    Impact:

    • Our results consolidated the evidence for treating all common retinal conditions, allowing the interpretation of the strength of the evidence of benefits and harms of the anti-VEGF drugs across conditions
    Funding:

    Canadian Institutes of Health Research (CIHR) through the Drug Safety and Effectiveness Network (DSEN)


    Anti–Vascular Endothelial Growth Factor Therapy for Age-related Macular Degeneration: Systematic Review and Network Meta-analysis

    Bottom Line:

    • Anti-VEGF agents are effective for improving vision gain, mean BCVA, and reducing vision loss for patients with wet AMD
    • Compared to placebo, we did not observe an association between their use and increased adverse events or mortality

    Impact:

    • Our results can be used by patients and their healthcare providers, as well as policy-makers to guide decision-making regarding use of the anti-VEGF agents

    Protocol:

    Additional Resources:

    Funding:

    Canadian Institutes of Health Research (CIHR) through the Drug Safety and Effectiveness Network (DSEN)

    Category :

    Date : 25 Aug 2017